Levodopa-related wearing-off in Parkinson's disease: identification and management

References

• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56:S1-S88
   PubMed Web of Science ®Google Scholar
• Strickland D, Bertoni JM. Parkinson's prevalence estimated by a state registry. Mov Disord 2004;19:318-23
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4
   PubMed Web of Science ®Google Scholar
• Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-54
   PubMed Web of Science ®Google Scholar
• Agid Y, Olanow CW, Mizuno Y. Levodopa: why the controversy? Lancet 2002;360:575
   PubMed Web of Science ®Google Scholar
• Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992;10:331-9
   PubMed Web of Science ®Google Scholar
• Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-26
   PubMed Web of Science ®Google Scholar
• Zappia M, Oliveri RL, Montesanti R, et al. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 1999;52:763-7
   PubMed Web of Science ®Google Scholar
• Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-305
   Google Scholar
• Adler CH. Relevance of motor complications in Parkinson's disease. Neurology 2002;58:51-6
   PubMed Web of Science ®Google Scholar
• Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord 2003;9:73-81
   Web of Science ®Google Scholar
• Obeso JA, Rodriguez-Oroz MC, Chana P, et al. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000;55:S13-20; discussion S1-3
   PubMedGoogle Scholar
• Lieberman A, Vijay M. Wearing-off of greatest concern for PD patient. Eur J Neurol 2004;11:S109 (Abstr P1284)
   Web of Science ®Google Scholar
• Koller W, Vijay M. Physician beliefs and practices in levodopa therapy for PD: results of a US National Survey. Eur J Neurol 2004;11:S9-35
   Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-9
   PubMed Web of Science ®Google Scholar
• Colosimo C, De Michele M. Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 1999;6:1-21
   PubMed Web of Science ®Google Scholar
• Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31
   PubMed Web of Science ®Google Scholar
• Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23:S2-7
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55:S72-7; discussion S8-81
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004;62:S72-81
   PubMed Web of Science ®Google Scholar
• Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004;62:S56-63
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-10
   PubMed Web of Science ®Google Scholar
• Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-62
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58
   PubMed Web of Science ®Google Scholar
• Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality. Mov Disord 1998;13:885-94
   PubMed Web of Science ®Google Scholar
• Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005;20:726-33
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508
   PubMed Web of Science ®Google Scholar
• Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408-13
   PubMed Web of Science ®Google Scholar
• Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996;47:1180-3
   PubMed Web of Science ®Google Scholar
• Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand 2001;104:312-15
   PubMed Web of Science ®Google Scholar
• Thanvi BR, Munshi SK, Vijaykumar N, et al. Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad Med J 2003;79:561-5
   PubMed Web of Science ®Google Scholar
• Stacy M, Hauser R, Oertel W, et al. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006;29:312-21
   PubMed Web of Science ®Google Scholar
• Stacy MA, Murphy JM, Greeley DR, et al. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2008;14:205-12
   PubMed Web of Science ®Google Scholar
• Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005;20:1502-7
   PubMed Web of Science ®Google Scholar
• Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-95
   PubMed Web of Science ®Google Scholar
• Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006;13:1186-202
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-39
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68:1108-15
   PubMed Web of Science ®Google Scholar